CYCCP News and Press, Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock From 03/01/21

The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this event. For further details see: Cyclacel Pharmaceuticals (CYCC) Investor Presentation - Slideshow

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2020 Results Conference Call February 25, 2021 04:30 PM ET Company Participants Jason Assad - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Dr. Ma...

BERKELEY HEIGHTS, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results and business hig...

BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 fina...

BERKELEY HEIGHTS, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the...

– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fundamental Investor Ac...

BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Bio...

- Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors - BERKELEY HEIGHTS, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals...

BERKELEY HEIGHTS, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Brian Schwartz,...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Eric Ando – Investor Relations Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President, Finance and Chief Opera...